



## **Ad hoc announcement pursuant to § 15 WpHG**

**Carl Zeiss Meditec reports revenue growth of 3.8% for 9M 2013/14 – EBIT close to previous year's level - EPS decline by 13%**

**Jena, 18 July 2014:** Carl Zeiss Meditec AG (ISIN: DE0005313704) reports revenue of approx. EUR 673.7m after 9M 2013/14 based on preliminary data. This corresponds to a growth rate of 3.8% vs. the previous year's level. Growth at constant currencies amounted to 7.3%.

Earnings before interest and taxes (EBIT) amounted to EUR 92.1m after 9M 2013/14. This corresponds to a slight decline of 1.4% vs. the previous year's level.

Earnings per share (EPS) after 9M 2013/14 amounted to EUR 0.71. This corresponds to a decline of approx. 13% vs. the previous year's level. The decline was mainly attributable to a negative result from currency hedging within the third quarter, compared to a markedly positive result from currency hedging in the previous year's quarter.

The 9M 2013/14 quarterly report will be published on 14 August 2014.

### **Contact for investors**

Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG  
Tel. +49 3641 220-116, E-Mail: [investors.meditec@zeiss.com](mailto:investors.meditec@zeiss.com)

### **Press contact**

Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec AG  
Tel. +49 3641 220-331, E-Mail: [press.meditec@zeiss.com](mailto:press.meditec@zeiss.com)

#### **Carl Zeiss Meditec AG**

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of € 906 million. The head office of Carl Zeiss Meditec is in Jena, Germany.

The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For more than 160 years Carl Zeiss has been contributing to the progress of technology on the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, improving the quality of life for many people. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.

For more information visit our website at:  
[www.meditec.zeiss.de](http://www.meditec.zeiss.de)